Literature DB >> 27901012

Correspondence Regarding the Study by Chen-Lu Yang et al. Published in the Chinese Medical Journal, 129(18):2258-9.

Alessandro Ferrari Jacinto1, Fábio Vicente Leite1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27901012      PMCID: PMC5146806          DOI: 10.4103/0366-6999.194651

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


× No keyword cloud information.
To the Editor: We read with interest the case report by Chen-Lu Yang et al.[1] of an elderly Chinese male diagnosed with an autoimmune disease (Wegener's granulomatosis) and an incidental diagnosis of monoclonal B lymphocytosis. Considering the immunophenotype, three types of monoclonal B lymphocytosis have been described: chronic lymphocytic leukemia (CLL), atypical CLL, and non-CLL (CD5−). The patient described in Chen-Lu Yang et al.'s study showed a small clonal B-lymphocyte population in the bone marrow, which was CD5−. It could be interesting to clarify to readers the patient's clinical aspects that led his doctors to require a bone marrow examination since there was no peripheral lymphocytosis. In case the medical staff considered it worthwhile to search for monoclonality for specific reasons, why didn't they first perform a flow cytometry of the peripheral blood? As the immunophenotype found was not CLL, the case report discussion should have been based more specifically on the association of non-CLL MBL (CD5−) and the progression to other malignant lymphoproliferative diseases. The term chronic B-cell lymphocytosis - marginal zone (CBL-MZ)[23] has been proposed for denominating cases with peripheral monoclonal B-cell lymphocytosis, resembling marginal zone lymphoma phenotype and no other clinical features such as splenomegaly or lymphadenopathy. The 2016 revision of the World Health Organization classification of lymphoid neoplasms has cited CBL-MZ as a provisional entity to be considered.[4] The patient in Yang's study could not be classified as CBL-MZ as no flow cytometry was performed on peripheral blood (and there was no clinical indication either). Therefore, would such a close follow-up with computed tomography and flow cytometry really be necessary? If the medical staff really considers it necessary, would flow cytometry of the peripheral blood be sufficient?

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features.

Authors:  Alessio Bruscaggin; Sara Monti; Luca Arcaini; Antonio Ramponi; Sara Rattotti; Marco Lucioni; Marco Paulli; Gianluca Gaidano; Davide Rossi
Journal:  Br J Haematol       Date:  2014-08-04       Impact factor: 6.998

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

3.  Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?

Authors:  Aliki Xochelli; Christina Kalpadakis; Anne Gardiner; Panagiotis Baliakas; Theodoros P Vassilakopoulos; Sarah Mould; Zadie Davis; Evangelia Stalika; George Kanellis; Maria K Angelopoulou; Neil McIver-Brown; Rachel Ibbotson; Sotirios Sachanas; Penelope Korkolopoulou; Anastasia Athanasiadou; Achilles Anagnostopoulos; Helen A Papadaki; Theodora Papadaki; Kostas Stamatopoulos; Gerassimos A Pangalis; David Oscier
Journal:  Blood       Date:  2013-12-03       Impact factor: 22.113

4.  Monoclonal B-cell Lymphocytosis in a Patient with Wegener Granulomatosis: A Case Report and Update on 2016 World Health Organization Classification.

Authors:  Chen-Lu Yang; Kai Shen; Qi-Bing Xie; Geng Yin
Journal:  Chin Med J (Engl)       Date:  2016-09-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.